Key facts
- Notable investors include Firstgate (South Korea), Korea Omega Investment, WOW Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for SimfliBIO
- ·The full record, as it builds
Funding rounds
No funding rounds for SimfliBIO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SimfliBIO
Developer of the liquid biopsy technique intended to perform less invasive gene mutation detection. The company detects gene mutations based on ctDNA in blood content using probes that complementarily bind to mutation-causing DNA or RNA sequences, helping physicians diagnose cancer using bodily fluids.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Ownership
- Privately Held (backing)
SimfliBIO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SimfliBIO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SimfliBIO in its N-PORT filings yet. We sweep new filings monthly.